Treatment of recurent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin

Tropé, Claes G.; Johnsson, J. E.; Simonsen, Ernst; Christiansen, Hans; Cavallin‐Ståhl, Eva; Horváth, György

doi:10.1016/0002-9378(84)90147-9

Cited by 53 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the metastatic or advanced setting, systemic treatment is palliative, and objective responses to treatment last on average 3–8 months (109, 110). Hormonal treatment and chemotherapy should be considered (111–113). One recent study demonstrated that the expression of hormone receptors (ERα) measured before hormonal therapy in metastatic endometrial carcinoma was significantly related to the clinical response (114).…”

Section: Treatmentmentioning

confidence: 99%

Biologic markers in endometrial cancer treatment

Engelsen

Akslen

Salvesen

2009

APMIS

View full text Add to dashboard Cite

With a lifetime risk among women of 2-3%, endometrial cancer is the most common pelvic gynecologic malignancy in industrialized countries. Approximately 75% of cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 15-20% with no signs of locally advanced or metastatic disease at primary treatment recurs, with limited responsiveness to systemic therapy. The most common basis for determining the risk of recurrent disease has been classification of endometrial cancers into two subtypes. Type I, associated with a good prognosis, accounts for the majority of cases and is associated with a low-stage, low-grade and endometrioid histology. In contrast, type II, associated with a poor prognosis, is characterized by a high-stage, high-grade and non-endometrioid histology. However, the prognostic value of this distinction is limited, as up to 20% of type I endometrial cancers recur, while half of type II cancers do not. We review the current literature on epidemiology, etiology, pathology, molecular alterations, staging, treatment and prognostic factors in endometrial cancer. Ongoing molecular-based clinical trials and newly reported molecular alterations with a potential for development of new targeted therapy are discussed.

show abstract

Section: Treatmentmentioning

confidence: 99%

Biologic markers in endometrial cancer treatment

Engelsen

Akslen

Salvesen

2009

APMIS

View full text Add to dashboard Cite

show abstract

“…These rates are relatively high for mTOR inhibitors, although they are generally lower compared to 43.3% (7) or 60.0% (35), previously reported for AP therapy and 63% (8) or 87% (9) previously reported for TC therapy for advanced or recurrent endometrial carcinoma, respectively, suggesting that there are several problems to be addressed regarding the use of molecular-targeted drugs. These include the multiplicity of carcinogenetic pathways and associated genes, rendering inhibition of a single molecule insufficient for anticancer activity.…”

Section: Molecular-targeted Drugs For Endometrial Cancermentioning

confidence: 63%

Current status of molecular-targeted drugs for endometrial cancer (Review)

Nogami

Banno

Kisu

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Endometrial cancer is a common gynecological malignant tumor in Western countries and its incidence has also been on the increase in Asia. Genetic abnormalities related to onset and progression of malignancy in the endometrial membrane and signaling system have been identified and the developmental mechanism of endometrial cancer is becoming elucidated. The identification of the molecules related to these abnormalities has led to new potential treatment regimens for endometrial cancer, using molecular-targeted drugs. The current chemotherapy for endometrial cancer often causes systemic side effects that require discontinuation of the treatment. Furthermore, a treatment regimen for cancers of rare histological types has not been established. Recent studies on endometrial cancer revealed patterns of genetic disorders that differ among the histological types. Genetic and molecular information that underlie pathological changes and is associated with DNA mismatch repair genes and epigenetic regulation was also identified. Targeting of these mechanisms with molecular-targeted drugs has been performed with the aim of linking treatment to the carcinogenic mechanism at the molecular and genetic levels. However, the response rates with single-agent therapy are generally low and several problems remain unresolved. Trials of combinations of molecular-targeted drugs with currently available treatments and identification of factors determining sensitivity are required to overcome these difficulties.

show abstract

“…The generally lower response rates of various targeted agents as compared with standard chemotherapy (43.3%−87%) [41–44] may be due to the multiplicity of carcinogenetic pathways and associated genes. Thus suppression of a single molecule may not be enough.…”

Section: Other Gynecologic Cancersmentioning

confidence: 99%